Compare Danaher Corporation (DHR) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Ferrari NV — how do they compare? Danaher Corporation trades at $219.52 (market cap $152.87B), while Ferrari NV trades at $388.82 (market cap $67.35B). The key difference: Danaher Corporation is far larger — about 2.3× Ferrari NV's market cap, and Ferrari NV pays the higher dividend (1.09%). Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Ferrari NV for 126 Days on average.
| DHR | RACE | |
|---|---|---|
Market Cap | $152.87B | $67.35B |
Volume | 5,228,698 | 390,618 |
Sector | Health | Consumer Cyclical |
52-Week High | $242.05 | $436.54 |
52-Week Low | $161.91 | $314.63 |
Typical Hold Time | 69 Days | 126 Days |
Enterprise Value | $175.08B | $69.22B |
Dividend Yield | 0.74% | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
Ferrari (RACE) trades at $390.13, up 0.97% today, with a bearish technical signal but strong fundamentals including 22.25% net income margin and consistent earnings beats. Revenue grew to $7.15B in 2025, and the company is executing a share buyback program. Analyst consensus is bullish with a $462.75 price target, though technical indicators show resistance near $390.
The stock offers upside based on premium brand strength and profitability, but faces risks from high valuation multiples (P/E 37.19) and economic sensitivity. Institutional accumulation and positive media coverage support sentiment, yet investors should weigh technical resistance against fundamental growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
